title: [Immune thrombocytopenias: pathophysiology and treatment].
abstract: Immune thrombocytopenia (ITP) is characterized by platelet destruction due to the presence of platelet antibodies. This phenomenon is associated with impaired platelet production by bone marrow. Short-course corticosteroids and high-dose intravenous immunoglobulins remain the first-line treatments. Several international guidelines propose splenectomy as a second-line treatment for chronic ITP. However, new therapeutic strategies including anti-CD20 monoclonal antibodies and thrombopoietin receptor agonists, appear to be very effective and to have good short-term tolerability. Prospective studies that include safety, efficacy and medico-economic assessments are needed to refine the management of chronic ITP.
authors.forename: Bertrand
authors.initials: B
authors.lastname: Godeau
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy* / Q000503:physiopathology*; D053628:Receptors, Thrombopoietin / Q000819:agonists; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D053628:Receptors, Thrombopoietin; D000069283:Rituximab